With its Phase II trial finally underway, Inovio has enlisted another key manufacturing partner to hit its goal of hundreds of millions of doses of its DNA vaccine — if it manages to force its old contract manufacturer into starting tech transfer. Japan’s Kaneka Eurogentec is tasked with plasmid production,
Read the full article at: endpts.com
